Chemotherapy infusion statistics at a glance
Chemotherapy infusion is not one single process. The numbers show a treatment path that changes by drug, setting, cancer type, and patient age, which makes the statistics more useful than a simple usage count.
If you want the fast version, this article pulls together the clearest chemotherapy infusion statistics from the supplied dataset and groups them into practical themes: delivery methods, care settings, cost drivers, and treatment patterns across cancer types.
Fast facts
- 7 delivery routes are listed for chemotherapy: oral, intravenous (IV), injection, intrathecal, intraperitoneal, intra-arterial, and topical (NCI Chemotherapy to Treat Cancer).
- IV is the most common chemotherapy method and can be delivered through a thin needle, catheter, or port, sometimes with a pump (NCI Chemotherapy to Treat Cancer).
- Chemotherapy can be given in 3 care settings: during a hospital stay, at home, or as an outpatient in a doctor’s office, clinic, or hospital (NCI Chemotherapy to Treat Cancer).
- Chemo is used for 2 main purposes: to treat cancer or ease cancer symptoms (NCI Chemotherapy to Treat Cancer).
- One example cycle described by NCI is 1 week of treatment followed by 3 weeks of rest, forming a 4-week cycle (NCI Chemotherapy to Treat Cancer).
Table of contents
- Chemotherapy infusion methods
- Care settings and treatment delivery
- Cost drivers and cycle structure
- Cancer type statistics and treatment patterns
- Metastatic colorectal therapy data
- What the age split suggests
Chemotherapy infusion methods
The most direct chemotherapy infusion statistics in the dataset start with delivery routes. That matters because chemotherapy is often discussed as if infusion were the default, but the supplied figures show a broader treatment toolkit.
Delivery methods in the dataset
| Method | What the supplied statistics say | Source |
|---|---|---|
| Oral | One of 7 chemotherapy delivery routes | NCI Chemotherapy to Treat Cancer |
| Intravenous (IV) | The most common chemotherapy method | NCI Chemotherapy to Treat Cancer |
| Injection | One of 7 chemotherapy delivery routes | NCI Chemotherapy to Treat Cancer |
| Intrathecal | One of 7 chemotherapy delivery routes | NCI Chemotherapy to Treat Cancer |
| Intraperitoneal | One of 7 chemotherapy delivery routes | NCI Chemotherapy to Treat Cancer |
| Intra-arterial | One of 7 chemotherapy delivery routes | NCI Chemotherapy to Treat Cancer |
| Topical | One of 7 chemotherapy delivery routes | NCI Chemotherapy to Treat Cancer |
The big takeaway is straightforward: IV chemotherapy is the most common method, but the route itself is only one part of the treatment picture (NCI Chemotherapy to Treat Cancer).
Why IV dominates the conversation
The supplied dataset says IV chemotherapy is delivered through a thin needle in a vein, catheter, or port, and it may sometimes use a pump (NCI Chemotherapy to Treat Cancer). That detail matters because the infusion experience is shaped by access method as much as by the drug itself.
A chemotherapy infusion statistic is therefore not just about frequency. It can also reflect how treatment is administered day to day:
- A thin needle can make a short visit feel very different from a port-based regimen.
- A catheter or port can support repeated treatment over time.
- A pump can change the practical rhythm of administration.
For readers comparing treatment experiences, the important point is that the same chemotherapy category can involve several administration styles, even before you get to the cancer being treated (NCI Chemotherapy to Treat Cancer).
Quick interpretation box
Key takeaway: the dataset does not frame chemotherapy as a single infusion event. It frames it as a family of delivery methods, with IV as the most common route and six other listed options available depending on treatment need (NCI Chemotherapy to Treat Cancer).
Care settings and treatment delivery
Another useful chemotherapy infusion statistic is where treatment happens. According to the supplied source, chemotherapy can be given in 3 broad care settings: during a hospital stay, at home, or as an outpatient in a doctor’s office, clinic, or hospital (NCI Chemotherapy to Treat Cancer).
That gives a practical way to read chemotherapy infusion statistics:
- Inpatient treatment may be used when closer monitoring is needed.
- Home treatment suggests a plan that can be managed outside a clinical facility.
- Outpatient treatment points to the most flexible and commonly discussed care pattern in routine cancer care settings (NCI Chemotherapy to Treat Cancer).
The dataset does not supply percentages for those settings, so the safest reading is structural rather than numerical. Still, the three-setting framework is useful because it shows that infusion is not always tied to one location.
At a glance: setting and administration
| Category | Supplied statistic | Source |
|---|---|---|
| Care settings | 3 broad settings | NCI Chemotherapy to Treat Cancer |
| Delivery routes | 7 routes | NCI Chemotherapy to Treat Cancer |
| Main uses | 2 purposes | NCI Chemotherapy to Treat Cancer |
| Example cycle | 1 week on, 3 weeks off | NCI Chemotherapy to Treat Cancer |
The combination of those figures points to a treatment model that is highly adaptable. A chemotherapy infusion may be one visit, one cycle, or one component of a broader care plan depending on the drug and cancer context.
Cost drivers and cycle structure
The supplied statistics do not give a single national price for chemotherapy, and that is important in itself. Instead, they list 4 cost factors that shape what chemotherapy can cost: drug type and dose, how long and how often it is given, where it is administered, and where the patient lives (NCI Chemotherapy to Treat Cancer).
That is a useful framework for anyone reading chemotherapy infusion statistics because it shows that cost is not determined by one variable alone.
The four cost drivers
- Drug type and dose influence the treatment plan directly.
- How long and how often it is given changes the total treatment burden (NCI Chemotherapy to Treat Cancer).
- Where it is administered can affect the care pathway.
- Where the patient lives may influence the overall cost picture (NCI Chemotherapy to Treat Cancer).
The dataset also includes one cycle example: 1 week of treatment followed by 3 weeks of rest, which creates a 4-week cycle (NCI Chemotherapy to Treat Cancer). That example is helpful because it explains why chemotherapy statistics often need a time dimension. A treatment can be periodic, not continuous.
Why treatment cycles matter in statistics
Cycle structure affects how people interpret chemotherapy infusion data:
- A single number can hide a repeated pattern of visits.
- A cycle can include both treatment weeks and recovery weeks.
- Time-on-treatment and time-off-treatment can both matter when describing care (NCI Chemotherapy to Treat Cancer).
In other words, chemotherapy infusion statistics are often more meaningful when paired with scheduling context. The dataset gives exactly that through the 4-week example cycle.
Cancer type statistics and treatment patterns
The most numerically detailed part of the dataset comes from cancer-specific treatment patterns. These figures do not describe infusion in the abstract; they show how often chemotherapy or related treatment approaches were used in specific cancers and years.
Selected treatment-use statistics
| Cancer type or context | Statistic | Source |
|---|---|---|
| Node-positive breast cancer, 2015 | 64.2% of women received multi-agent chemotherapy | Cancer Trends Progress Report 2024 |
| Invasive stage I or II breast cancer, 2020 | 31.8% received mastectomy | Cancer Trends Progress Report 2024 |
| Invasive stage I or II breast cancer, 2020 | 50.4% received breast-conserving surgery with radiation | Cancer Trends Progress Report 2024 |
| Invasive stage I or II breast cancer, 2020 | 17.7% received breast-conserving surgery without radiation | Cancer Trends Progress Report 2024 |
| Stage III colon and stage II/III rectal cancer, 2015 | 70.3% received guideline-concordant chemotherapy | Cancer Trends Progress Report 2024 |
| Localized/regional kidney cancer, 2020 | 35.3% received a partial nephrectomy | Cancer Trends Progress Report 2024 |
| Localized/regional kidney cancer, 2020 | 43.4% received a complete nephrectomy | Cancer Trends Progress Report 2024 |
| Stage IIIB/IV non-small cell lung cancer, 2017 to 2018 | 61.9% of patients aged 20 and older received chemotherapy | Cancer Trends Progress Report 2024 |
| Stage III or IV melanoma of the skin, 2018 | 79.4% of patients aged 20 and older received chemotherapy | Cancer Trends Progress Report 2024 |
| Stage III or IV ovarian cancer, 2011 | 79.9% of patients received chemotherapy | Cancer Trends Progress Report 2024 |
These statistics are not interchangeable. Each one sits in a specific cancer context, which is why the source label matters. A breast cancer treatment figure should not be read as if it applies to lung cancer, and a chemotherapy utilization rate should not be treated as a universal benchmark.
What stands out across cancer types
A few patterns are visible from the supplied numbers alone:
- Chemotherapy use can be very high in advanced disease contexts, such as 79.9% in stage III or IV ovarian cancer and 79.4% in stage III or IV melanoma of the skin, both in the Cancer Trends Progress Report 2024.
- Guideline-concordant chemotherapy can also be substantial in colorectal cancer, with 70.3% in stage III colon and stage II/III rectal cancer in 2015 (Cancer Trends Progress Report 2024).
- Treatment patterns differ by cancer and year, which is why the same chemotherapy keyword can cover very different clinical realities.
Stat callout
Big number: 79.9% of stage III or IV ovarian cancer patients received chemotherapy in 2011 (Cancer Trends Progress Report 2024).
That single figure is useful because it anchors the upper end of the supplied chemotherapy usage statistics in a clearly defined cancer stage.
What the age split suggests
The age-based colorectal and lung cancer figures add another layer of detail. They show that chemotherapy use can vary sharply by age group even within the same cancer context.
Age-related chemotherapy statistics
| Cancer context | Age group | Statistic | Source |
|---|---|---|---|
| Stage IIIB/IV non-small cell lung cancer | 20 to 49 | 88.6% received chemotherapy | Cancer Trends Progress Report 2024 |
| Stage IIIB/IV non-small cell lung cancer | 50 to 59 | 74.6% received chemotherapy | Cancer Trends Progress Report 2024 |
| Stage IIIB/IV non-small cell lung cancer | 60 to 69 | 62.1% received chemotherapy | Cancer Trends Progress Report 2024 |
| Stage IIIB/IV non-small cell lung cancer | 70 to 79 | 59.2% received chemotherapy | Cancer Trends Progress Report 2024 |
| Stage IIIB/IV non-small cell lung cancer | 80 and older | 40.6% received chemotherapy | Cancer Trends Progress Report 2024 |
| Colorectal patients | Younger than 65 | 86.9% guideline-concordant chemotherapy rate | Cancer Trends Progress Report 2024 |
| Colorectal patients | 65 and older | 57.1% guideline-concordant chemotherapy rate | Cancer Trends Progress Report 2024 |
The pattern is clear: the supplied figures show lower chemotherapy use in older age groups.
Why the age difference matters
The non-small cell lung cancer numbers move from 88.6% in the 20 to 49 group down to 40.6% in the 80 and older group (Cancer Trends Progress Report 2024). That is a wide span, and it suggests age is a major contextual factor in treatment use.
The colorectal data shows the same direction: 86.9% guideline-concordant chemotherapy for patients younger than 65 versus 57.1% for those 65 and older (Cancer Trends Progress Report 2024).
For a reader trying to understand chemotherapy infusion statistics, that means the headline is not just “how often chemo is used.” It is also “for whom, at what age, and in which cancer setting.”
Short reading guide
- Higher percentages in younger groups may reflect treatment suitability, but the dataset itself does not explain why.
- Lower percentages in older groups are consistent across the supplied lung and colorectal figures.
- The numbers are descriptive, not explanatory, so they should be read as pattern indicators rather than causes.
Metastatic colorectal therapy data
The metastatic colorectal cancer section is the most detailed treatment-pathway dataset in the list. It shows how patients move across drug classes and therapy lines, which makes it especially relevant for readers looking for chemotherapy infusion statistics that reflect real treatment sequencing.
Drug exposure and treatment lines
- 11% of patients received all 5 therapeutic drug classes studied (PMC2988664).
- 19% received 3 or more therapeutic drug classes (PMC2988664).
- 49% were exposed to FOLFOX at any line (PMC2988664).
- 28% were exposed to FOLFIRI at any line (PMC2988664).
- 69% were exposed to bevacizumab at any time (PMC2988664).
- 22% were exposed to cetuximab at any time (PMC2988664).
- 7% were exposed to panitumumab at any time (PMC2988664).
The first thing to notice is how fragmented treatment exposure can be. Only 11% of patients received all 5 therapeutic drug classes studied, and 19% received 3 or more classes (PMC2988664). That points to a treatment landscape where many patients do not pass through every available class.
First-, second-, and third-line patterns
| Therapy line | Statistic | Source |
|---|---|---|
| First-line metastatic colorectal therapy | FOLFOX used in 40.5% of patients | PMC2988664 |
| Patients receiving first-line therapy | 44.8% went on to second-line therapy | PMC2988664 |
| Patients receiving first-line therapy | 19.2% went on to third-line therapy | PMC2988664 |
| Second-line metastatic colorectal therapy | FOLFIRI used in 25.7% of patients | PMC2988664 |
| Second-line metastatic colorectal therapy | FOLFIRI alone used in 4.2% of patients | PMC2988664 |
| Second-line metastatic colorectal therapy | FOLFIRI with biologics used in 21.5% of patients | PMC2988664 |
| Second-line metastatic colorectal therapy | FOLFIRI with bevacizumab used in 18.3% of patients | PMC2988664 |
| Second-line metastatic colorectal therapy | FOLFIRI with cetuximab used in 3.2% of patients | PMC2988664 |
| Second-line metastatic colorectal therapy | FOLFOX with bevacizumab used in 17.0% of patients | PMC2988664 |
| Second-line metastatic colorectal therapy | Cetuximab plus irinotecan used in 8.5% of patients | PMC2988664 |
Treatment duration data
- Mean treatment duration for bevacizumab plus FOLFIRI was 4.61 months (PMC2988664).
- Mean treatment duration for bevacizumab plus FOLFOX was 4.28 months (PMC2988664).
- Mean treatment duration for cetuximab plus irinotecan was 3.20 months (PMC2988664).
- In third-line therapy, cetuximab plus irinotecan had a mean duration of 2.77 months (PMC2988664).
- Panitumumab monotherapy had a mean duration of 2.63 months in third-line therapy (PMC2988664).
- Cetuximab monotherapy had a mean duration of 1.99 months in third-line therapy (PMC2988664).
The duration figures give the treatment pathway more texture. They suggest that later-line treatment can still involve meaningful time on therapy, but the exact duration depends on the regimen (PMC2988664).
Pull-quote style highlight
Notable pattern: In metastatic colorectal cancer, 44.8% of patients who received first-line therapy went on to second-line therapy, while 19.2% went on to third-line therapy (PMC2988664).
That pair of percentages is a strong reminder that treatment sequences can narrow quickly after the first line.
Reading chemotherapy infusion statistics correctly
The dataset gives enough information to build a careful reading strategy for chemotherapy infusion statistics:
- Start with the delivery route before assuming the treatment format.
- Check the care setting because hospital, home, and outpatient delivery can all appear in the same treatment category (NCI Chemotherapy to Treat Cancer).
- Use cycle structure to understand time-based treatment patterns.
- Compare percentages only within the same cancer context and year.
- Keep source labels visible, because the same keyword covers both general treatment guidance and disease-specific treatment rates.
The main value of these numbers is that they prevent oversimplification. “Chemotherapy infusion” sounds like one thing, but the dataset shows a wider operational reality: seven route options, three care settings, two broad purposes, a sample four-week cycle, and multiple cancer-specific utilization patterns across years and age groups (NCI Chemotherapy to Treat Cancer; Cancer Trends Progress Report 2024; PMC2988664).
When the stats are grouped this way, the keyword becomes much more informative. It is not just about infusion as a procedure. It is about how chemotherapy is delivered, where it happens, how it is sequenced, and how often it appears in different cancer settings.